Synthesis of (5R)- and (5S)-5-Methyl-5, 6-dihydrouridine Derivatives

The hydrogenation of 2′, 3′-O-isopropylidene-5-methyluridine (1) in water over 5% Rh/Al₂O₃ gave (5 R)- and (5 S)-5-methyl-5, 6-dihydrouridine (2) , separated as 5′-O-(p-tolylsulfonyl)- (3) and 5′-O-benzoyl- (5) derivatives by preparative TLC. on silica gel and ether/hexane developments. The diastereoisomeric differentiation at the C(5) chiral centre depends upon the reaction media and the nature of the protecting group attached to the ribosyl moiety. The synthesis of iodo derivatives (5 R)- and (5 S)- 4 is also described. The diastereoisomers 4 were converted into (5 R)- and (5 S)-2′, 3′,-O-isopropylidene-5-methyl-2, 5′-anhydro-5, 6-dihydrouridine (7) .     

Dihydrodiazepine aus valenzisomeren diazatricyclo[3.2.0.0.2,4]Heptanen1)

Cycloaddition of diazoalkanes to diazabicyclo[2.2.0]hexenes and subsequent extrusion of nitrogen afford diazatricyclo[3.2.0.0^2,4]heptanes that are easily valence isomerized to novel dihydrodiazepines.     

Synthesis of ribonucleosides of 4(5)-cyano-5(4)-methylimidazole and related 4-substituted-5-methylimidazole ribosides

4-Cyano-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-5-methylimidazole ( 4 ) and its corresponding 5-cyano-4-methyl substituted isomer ( 5 ) have been obtained by ribosylation of 4(5)-cyano-5(4)-methylimidazole ( 3 ) via the mercuric cyanide method or by ribosylation of the trimethylsilyl derivative of 3 . Treatment of 4 with methanolic ammonia, ammonium chloride in liquid ammonia and potassium hydrosulfide provided 4-cyano-1-β-D-ribofuranosyl-5-methylimidazole ( 6 ), 1-β-D-ribofuranosyl-5-methylimidazole-4-carboxamide ( 2 ) and 1-β-D-ribofuranosyl-5-methylimidazole-4-thiocarboxamide ( 11 ) respectively. Reaction of 6 with hydroxylamine afforded the corresponding 4-carboxamidoxime substituted nucleoside ( 13 ) which on catalytic reduction in the presence of ammonium chloride, was transformed into 1-β-D-ribofuranosyl-5-methylimidazole-4-carboxamidine ( 14 ) as hydrochloride salt.     

Synthesis and biological evaluation of 5-substituted-4-nitroimidazole ribonucleosides

The imidazole nucleosides, 4(5)-bromo-5(4)-nitro-1-β-D-ribofuranosylimidazoles, have been prepared via glycosylation of the trimethylsilylated aglycone, 4(5)-bromo-5(4)-nitroimidazole, with tetra-O-acetyl-β-D-ribo-furanose followed by removal of the acetyl protecting groups. The 5-bromo-4-nitro-1-β-D-ribofuranosylimidazole nucleoside was acetonated to produce 5-bromo-4-nitro-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)-imidazole which was cyclized to provide the corresponding anhydronucleoside 5,5′-anhydro-4-nitro-5-oxo-1-(2,3-O-isopropylidene-β-D-ribofuranosyl)imidazole. Sodium hydrosulfide treatment of 5-bromo-4-nitroimidazole nucleoside provided 5-mercapto-4-nitro-1-β-D-ribofuranosylimidazole 5-sodium salt which was alkylated with E-1,5-diiodopent-1-ene to yield 5-(E-1-iodo-1-penten-5-yl)thio-4-nitro-1-β-D-ribofuranosylimidazole. The corresponding iodine-125-labeled compound was prepared similarly using radiolabeled diiodopentene. The 5-bromo-4-nitroimidazole, 5-mercapto-4-nitroimidazole, and 5-iodopentenylthio-4-nitroimidazole nucleosides were cytotoxic to Molt-3 cells in vitro at concentrations higher than 10 μg/mL. The radiolabeled 5-iodopentenylthio-4-nitroimidazole nucleoside showed 2-fold higher uptake in a rapidly growing tumor as compared to uptake in a relatively slower growing tumor in mice.     

The enantioselective synthesis of (4S,5S)- and (4S,5R)-5-hydroxy-4-decanolide,the autoregulators from Strepotomyces griseus

(4S, 5S)- and (4S, 5R)-5-Hydroxy-4-decanolide ( 1a and 1b ), the proposed autoregulators from Strepotomyces Griseus were synthesized from a propargyl alcohol 2 in an overall yield of 30%, employing the Sharpless asymmetric epoxidation as the key step.     

Monohalogenated ferrocenes C5H5FeC5H4X (X = Cl,Br and I) and a second polymorph of C5H5FeC5H4I

The structures of the three title monosubstituted ferrocenes, namely 1‐chloroferrocene, [Fe(C₅H₅)(C₅H₄Cl)], (I), 1‐bromoferrocene, [Fe(C₅H₅)(C₅H₄Br)], (II), and 1‐iodoferrocene, [Fe(C₅H₅)(C₅H₄I)], (III), were determined at 100 K. The chloro‐ and bromoferrocenes are isomorphous crystals. The new triclinic polymorph [space group P, Z = 4, T = 100 K, V = 943.8 (4) ų] of iodoferrocene, (III), and the previously reported monoclinic polymorph of (III) [Laus, Wurst & Schottenberger (2005). Z. Kristallogr. New Cryst. Struct. 220 , 229–230; space group Pc, Z = 4, T = 100 K, V = 924.9 ų] were obtained by crystallization from ethanolic solutions at 253 and 303 K, respectively. All four phases contain two independent molecules in the unit cell. The relative orientations of the cyclopentadienyl (Cp) rings are eclipsed and staggered in the independent molecules of (I) and (II), while (III) demonstrates only an eclipsed conformation. The triclinic and monoclinic polymorphs of (III) contain nonbonded intermolecular I...I contacts, causing different packing modes. In the triclinic form of (III), the molecules are arranged in zigzag tetramers, while in the monoclinic form the molecules are arranged in zigzag chains along the a axis. Crystallographic data for (III), along with the computed lattice energies of the two polymorphs, suggest that the monoclinic form is more stable.     

Synthesis of 4-aroyl-5-nitro-1H-imidazoles and 4-aroyl-5-aminoimidazoles

The reaction of α-(aryl)-4-morpholineacetonitriles (masked aroyl anion equivalents) with N-protected 4(5)-bromo-5(4)-nitro-1H-imidazoles gave 4-aroyl-5-nitroimidazoles which were reduced to afford 4-aroyl-5-aminoimidazoles.     

5a-Carba-β-D-, 5a-Carba-β-L- and 5-Thio-β-L-xylopyranosides as New Orally Active Venous Antithrombotic Agents

Mitsunobu displacement of (−)-(1S,4R,5S,6S)-4,5,6-tris{[(tert-butyl)dimethylsilyl]oxy}cyclohex-2-en-1-ol ((−)- 12 ; a (−)-conduritol-F derivative) with 4-ethyl-7-hydroxy-2H-1-benzopyran-2-one ( 16 ) provided a 5a-carba-β-D -pyranoside (+)- 17 that was converted into (+)-4-ethyl-7-[(1′R,4′R,5′S,6′R)-4′,5′,6′-trihydroxycyclohex-2′-en-1′-yloxy]-2H-1-benzopyran-2-one ((+)- 5 ) and (+)-4-ethyl-7-[(1′R,2′R,3′S,4′R)-2′,3′,4′-trihydroxycyclohexyloxy]-2H-1-benzopyran-2-one ((+)- 6 ). The 5a-carba-β-D -xyloside (+)- 6 was an orally active antithrombotic agent in the rat (venous Wessler's test), but less active than racemic carba-β-xylosides (±)- 5 and (±)- 6 . The 5a-carba-β-L -xyloside (−)- 6 was derived from the enantiomer (+)- 12 and found to be at least 4 times as active as (+)- 6 . (+)-4-Cyanophenyl 5-thio-β-L -xylopyranoside ((+)- 3 ) was synthesized from L -xylose and found to maintain ca. 50% of the antithrombotic activity of its D -enantiomer. Compounds (±)- 5 , (±)- 6 , and (−)- 6 are in vitro substrates for galactosyltransferase 1.     

Synthesis of S-5-pyrrolo[2,3-b]pyridinemethyl and S-5- and S-6-pyrrolo[2,3-d]pyridinemethyl derivatives of 5′-deoxy-5′-thioadenosine

Reaction of 5-dimethylaminomethylpyrrolo[2,3-b]pyridine methiodide or 5-dimethylaminomethylpyrrolo[2,3-d]pyrimidin-4-one methiodide with 5′-deoxy-5′-S-thioacetyl-N⁶-formyl-2′,3′-O-isopropylideneadenosine in ethanolic sodium hydroxide solution, followed by deprotection of the resulting thioether in 80% formic acid, afforded 5′-deoxy-5′-(5-pyrrolo[2,3-b]pyridinemethylthio)adenosine or 5′-deoxy-5′-[5-(pyrrolo[2,3-d]pyrimidin-4-one)methylthio]adenosine, respectively. Similarly, the metiodide salt of the iso-gramine analog, 2-amino-6-dimethylaminomethylpyrrolo[2,3-d]pyrimidin-4-one afforded 5′-deoxy-5′-[6-(2-aminopyrrolo[2,3-d]pyrimidin-4-one)methylthio]adenosine.     

Reactions of ethyl 4-chloro-5-pyrimidinecarboxylates with 2-aminopyridine. Synthesis of 5H-pyrido[1,2-A]pyrimido[5,4-e]pyrimidin-5-ones and 5H-pyrido[1,2-a]pyrimido[4,5-d]pyrimidin-5-ones and rearrangement of the former to the latter

5H-Pyrido[1,2-a]pyrimido[5,4-e]pyrimidin-5-ones IVa,b and 5H-pyrido[1,2-a]pyrimido[4,5-d]pyrimidin-5-ones Va,b were synthesized from ethyl 4-chloro-5-pyrimidinecarboxylate and 2-aminopyridine. The former compounds were obtained directly upon heating the reactants in ethanol, and the latter were prepared by the fusion of ethyl 4-(2-pyridylamino)-5-pyrimidinecarboxylates obtained as minor products from the above reaction. The angular fused cyclic compounds, IVa,b were rearranged to the linear tricycles, Vb-f upon heating with amines.     

Synthesis of 5-Methyluridine and Its 5′-Mercapto-, 2-Amino-, and 4′,5′-Unsaturated Analogues

The stereospecific cis-hydroxylation of 1-(2,3-dideoxy-β-D -glyceropent-2-enofuranosyl)thymine (1) into 1-β-D -ribofuranosylthymine (2) by osmium tetroxide is described. Treatment of 2′,3′-O, O-isopropylidene-5-methyl-2,5′-anhydrouridine (8) with hydrogen sulfide or methanolic ammonia afforded 5′-deoxy-2′,3′-O, O-isopropylidene-5′-mercapto-5-methyluridine (9) and 2′,3′-O, O-isopropylidene-5-methyl-isocytidine (10) , respectively. The action of ethanolic potassium hydroxide on 5′-deoxy-5′-iodo-2′,3′-O, O-isopropylidene-5-methyluridine (7) gave rise to the corresponding 1-(5-deoxy-β-D -erythropent-4-enofuranosyl)5-methyluracil (13) and 2-O-ethyl-5-methyluridine (14) . The hydrogenation of 2 and its 2′,3′-O, O-isopropylidene derivative 4 over 5% Rh/Al₂O₃ as catalyst generated diastereoisomers of the corresponding 5-methyl-5,6-dihydrouridine ( 17 and 18 ).     

Pyridine nucleosides related to 5-fluorocytosine

4-Amino-5-fluoro-2-pyridone ( 4 ) [5-fluoro-3-deazacytosine] was isolated as the hydrochloride salt from the dealkylation of 4-amino-5-fluoro-2-methoxypyridine ( 2 ), which was obtained from the reduction of 5-fluoro-2-methoxy-4-nitropyridine-N-oxide ( 1 ). Acetylation of 2 gave 4-acetamido-5-fluoro-2-methoxypyridine ( 3 ), which was condensed with 2,3,5-tri-O-benzoyl-D-ribofuranosyl bromide to give the blocked nucleoside ( 8 ). Removal of the protecting groups gave 5-fluoro-3-deazacytidine. Fusion of the trimethylsilyl derivative of 4 (10), with 2-deoxy-3,5-di-O-p-toluoyl-D-erythro pentofuranosyl chloride gave a mixture of the β and α-anomers 12 and 13 , which were separated and deblocked to yield 5-fluoro-2′-deoxy-3-deazacytidine ( 14 ) and its α-anomer ( 15 ). Several alkylated and acetylated derivatives of 2 were prepared as model compounds for use in the proof of structure.     

Further evaluation of 5-alkyl-5-deaza antifolates. 5-propyl- and 5-butyl-5-deaza analogues of aminopterin and methotrexate

5-Propyl-5-deaza and 5-butyl-5-deaza analogues of classical antifolates were synthesized by extensions of a previously reported general route which proceeds through 2,4-diamino-5-alkylpyrido[2,3-d]pyrimidine-6-carbonitrile intermediates followed by reductive condensation with diethyl N-4-(aminobenzoyl)-L-glutarnate to give diethyl esters of 5-alkyl-5-deazaaminopterin types. N¹⁰-Methyl derivatives, i.e., derivatives of 5-alkyl-5-deazamethotrexate, were also prepared by reductive methylation of the N¹⁰-H compounds. 5-Ethyl-5-deazamethotrexate was prepared using an alternative route through 6-(bromomethyl)-2,4-diamino-5-ethylpyrido[2,3-d]pyrimidine. These antifolates were evaluated for inhibition of dihydrofolate reductase (DHFR) from L1210 cells, their effect on L1210 and S180 tumor cell growth in culture, and carrier-mediated transport through L1210 cell membranes. Inhibitory effect on DHFR was lowered relative to methotrexate in 5-propyl-5-deazaaminopterin and 5-propyl-5-deazamethotrexate by 2- to 3-fold (K_i = 9.3 and 11.7 pM, respectively, vs. 4.3 pM for methotrexate) and by 17- to 18-fold in 5-butyl-5-deaza-aminopterin and 5-butyl-5-deazamethotrexate (K_i = 74 and 78 pM, respectively). Molecular modeling using graphics derived from human DHFR show the propyl and butyl compounds interacting with the enzyme in conformations that account for these slight decreases in binding.     

Phase-transition studies of 5O.5 and 9O.4

As part of our detailed comparative studies of groups of liquid-crystalline compounds that belong to a homologous series, we present phase-transition studies of the compounds N-(4-n-pentyloxybenzylidene)4′-n-pentylaniline (5O.5) and N-(4-n-nonyloxybenzylidene)4′-n-butylaniline (9O.4) using different experimental techniques. The compound 5O.5 is reported to exhibit a phase sequence N, S_A, S_C, S_B and S_G, while 90.4 shows the sequence S_A, S_F and S_G. The salient features of our work on 5O.5 are (i) a new smectic F phase is found in place of the reported smectic B phase, which is confirmed by both miscibility and X-ray studies; (ii) the formation of smectic-C-like short-range order in the nematic phase well above the S_A-N transition; and (iii) a large tilt-angle variation in the smectic C phase (0–23·5°C) in a small temperature range (4·1°C). The phase changes across the S_A-I transition, and for the first time across S_F-S_A transition, are carried out by volumetric studies. The detailed inferences of these are also presented.     

Studies on structurally simple α,β-butenolides. VIII. 5-Haloalkyl- and 3-bromo-5-hydroxyalkyl-2(5H)-furanones

Bromine and NBS react with sorbic acid to yield bromohydrin 5 and bromolactones 4 , respectively. The erythro and threo isomers 4a,b were separated and the crystal structure of the former was determined. Bromolactone 7 , as a single erythro stereoisomer, was prepared by photolactonization of 5 .     

Novel tris(5-aryl-1H-tetrazol-1-yl)methanes and 2-dichloromethyl-5-aryl-2H-tetrazoles and noncovalent interactions in their crystal structure

A series of tris(5-aryl-1H-tetrazol-1-yl)methanes ( 3a-3g ) and 2-dichloromethyl-5-aryl-2H-tetrazoles ( 4a-4d ) were synthesized by reaction of 5-aryl-NH-tetrazoles with trichloromethane in strong aqueous basic condition. The compounds obtained were fully characterized by means of HRESI-MS, ¹H and ¹³C{¹H} NMR spectroscopies, as well as by single-crystal X-ray diffraction (for 3a , 3b , 4d ). Inspection of the X-ray diffraction data and Hirshfeld surface analysis for tris(5-aryl-1H-tetrazol-1-yl)methanes 3a , b and 2-dichloromethyl-5-aryl-2H-tetrazole 4d showed the presence of noncovalent π-hole•••lone pair and π-hole•••π interactions involving electrophilic tetrazole carbon atom.     

Oxetane from A-nor-steroides: 2-alpha, 5-oxido-A-nor-5-alpha-cholestane, 2-beta, 5-oxido-A-nor-5-beta-cholestane and 2-alpha-ethyl-2-beta,2'-oxido-A-nor-5-alpha-cholestane

Treatment of 2β-tosyloxy-A-nor-5α-cholestane-5-ol ( 2 ) with t-butoxide in t-butanol gave 2α, 5-epoxy-A-nor-5α-cholestane ( 3 ) in quantitative yield. When A-nor-5β-cholestane-2α, 5-diol ( 4 ) was treated with tosyl chloride in pyridine 2β-chloro-A-nor-5β-cholestane-5-ol ( 7 ) and 2α-tosyloxy-A-nor-5β-cholestane-5-ol ( 8 ) were obtained. Whereas the chloride 7 was resistant to t-butoxide the tosylate 8 was transformed into an 1 : 1 mixture of 2α, 5-epoxy-5β-cholestane ( 10 ) and 2ξ-t-butoxy-A-nor-5β-cholestane-5-ol ( 11 ). In 2α-tosyloxy-A-nor-5α-cholestane-5-ol ( 12 ) substitution occurred as the only reaction. Both oxetanes 3 and 10 isomerize after heating above 50° and in polar or protic solvents to form A-nor-Δ³⁽⁵⁾-cholestene-2α-ol ( 6 ) and -2β-ol ( 14 ) respectively. Also, 2, 5-diols are encountered. 2α-Ethyl-2β, 2′-epoxy-A-nor-5α-cholestane ( 23 ) was synthesized starting from A-nor-5α-cholestane-2-one ( 17 ). The intermediates were the ester 16 , the diol 18 , the hydroxy-tosylate 19 and the chlorhydrin 20 . The spirocyclic oxetane 23 was reduced by LiAlH₄ in dioxane (not in ether). By chromatography on silica gel 23 was isomerized to the homoallylic alcohol 21 and transformed into 2-methylene-A-nor-5α-cholestane ( 24 ) by fragmentation. The IR. and NMR. spectra of the new oxetanes were compared with those of a series of known oxetanes.     

Quasirelativistic energy-consistent 5f-in-core pseudopotentials for divalent and tetravalent actinide elements

Quasirelativistic energy-consistent 5f-in-core pseudopotentials modeling divalent (5f ⁿ⁺¹ occupation with n = 5–13 for Pu–No) respectively tetravalent (5f ^n-1 occupation with n = 1–9 for Th–Cf) actinides together with corresponding core-polarization potentials have been generated. Energy-optimized (6s5p4d) and (7s6p5d) valence basis sets as well as 2f1g correlation functions have been derived and contracted to polarized double, triple, and quadruple zeta quality. Corresponding smaller (4s4p) and (5s5p) respectively (4s4p3d) and (5s5p4d) basis sets suitable for calculations on actinide(II) respectively actinide(IV) ions in crystalline solids form subsets of these basis sets designed for calculations on molecules. Results of Hartree–Fock test calculations for actinide di- and tetrafluorides show a satisfactory agreement with calculations using 5f-in-valence pseudopotentials. Electronic Supplementary Material The online version of this article doi: contains supplementary material, which is available to authorized users.     

2,6-Dithiodecahydro-1H,5H-Diimidazo[4,5,-b:4′,5′-e]Pyrazine and related dioxo- and diimino-decahydrodiimidazopyrazines

Thiourea condensed with 1,4-diformyl-2,3,5,6-tetrahydroxypiperazine 2 in the presence of hydrochloric acid to give 2,6-dithiodecahydro-1 H,5H-diimidazo[4,5,-b:4′,5′-e]pyrazine 5 isolated as the dihydrochloride salt. The salt 5 . 2HCl was converted to the free base 5 by lithium hydroxide, to the dinitrate salt 5 . 2HNO₃ by silver nitrate, degraded to 2-thio-2,3,4,7-tetrahydro-1 H-imidazo[4,5-b]pyrazine 6 in a reaction with tert-butyl amine, and converted to 4,8-dihydro-4,8-dinitro-1H,5H-diimidazo[4,5-b:4′,5′-e]pyrazine-2,6- disulfonic acid 9 by nitric acid (100%) at −40°C. Denitration of the dinitramine 9 to give 4,8-dihydro-1H,5H-diimidazo[4,5-b:4′,5′-e]pyrazine 11 was brought about by methanolic hydrogen chloride in ether. In one run nitration without oxidation converted the salt 5 · 2HCl to the dinitrate salt of the 4,8-dinitro derivative 10 ; treatment with triethyl amine liberated the free base 10 from the salt. Degradation of 2,6-dioxo-1,3,4,5,7,8-hexanitrodecahydro-1H,5H-diimidazo[4,5-b:4′,5′-e]pyrazine 12 to 2-oxo-2,3-dihydro-1,3-dinitro-1H-imidazo[4,5-b] pyrazine 13 was brought about by hydrochloric acid. Treatment with lithium hydroxide also liberated 2,6-dioxodecahydro-1H,5H-diimidazo [4,5-b:4′,5′-e]pyrazine 3 from its dihydrochloride salt. Attempts to liberate 2,6-diiminodecahydro-1H, 5H-diimidazo[4,5-b:4′,5′-e]pyrazine 4 from its tetrahydrochloride salt led instead to intractable mixtures. The tetrahydrochloride salt 4 · 4HCl was converted to the dihydrochloride salt 4 · 2HCl in a reaction with tert-butyl amine.